Brief: Alzinova Gets FDA IND Approval For Phase II Study Of Alz-101 In Alzheimer's Disease
04/09/2025 11:32
Sept 4 (Reuters) - Alzinova AB ALZ.ST: RECEIVES FDA (IND) APPROVAL FOR PHASE II STUDY OF ALZ-101 IN ALZHEIMER'S DISEASE Source text: ID:nMFN8ndZb9 Further company coverage: ALZ.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Alzinova AB
See all newsBrief: Alzinova's Board Resolves On Directed Issue Of Units
Brief: Alzinova Announces Preliminary Outcome Of The Rights Issue
Brief: Alzinova Broadens Shareholder Base With New Investor
Brief: Alzinova Resolves On Rights Issue Of SEK 51 Mln
Brief: Alzinova Q2 Loss After Financial Items At SEK 5.4 Million